Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listN-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine

N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine

  • CAS NO.:881202-45-5
  • Empirical Formula: C21H20N4
  • Molecular Weight: 328.41
  • MDL number: MFCD16620518
  • EINECS: 200-256-5
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-01 18:44:47
N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine Structural

What is N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine?

The Uses of N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine

JNJ 26854165 is a p53 activator and HDM2 ubiquitin ligase (MDM2) inhibitor.

What are the applications of Application

JNJ 26854165 is a p53 activator and HDM2 ubiquitin ligase (MDM2) inhibitor

Biological Activity

jnj-26854165, also named as serdemetan, is originally developed as an activator of p53, is now regarded as a novel oral human double minute-2 (hdm-2) ubiquitin ligase antagonist. it can increase the level of hdm-2 client proteins, such as p53, by inhibiting the association of hdm-2-client protein complex with the proteosome. it is demonstrated potent anti-proliferative and apoptosis-inducing activity of jnj-26854165 in a broad range of p53 wild type and mutant tumor models. in vivo, jnj-26854165 may induce important differences in efs distribution when comparing to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable all xenografts.j. tabernero, l. dirix, p. schoffski, a. cervantes, j. capdevila, j. baselga, l. van beijsterveldt, h. winkler, s. kraljevic and s. h. zhuang. phase i pharmacokinetic (pk) and pharmacodynamic (pd) study of hdm-2 antagonist jnj-26854165 in patients with advanced refractory solid tumors. journal of clinical oncology (meeting abstracts) may 2009 vol. 27 no. 15s 3514malcolm a. smith, richard gorlick, e. anders kolb, richard lock, hernan carol, john m. maris, stephen t. keir, christopher l. morton, c. patrick reynolds, min h. kang, janine arts, tarig bashir, michel janicot, raushan t. kurmasheva, peter j. houghton. initial testing of jnj-26854165 (serdemetan) by the pediatric preclinical testing program. pediatric blood & cancer. volume 59, issue 2, pages 329–332, august 2012.

Properties of N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine

storage temp.  Store at -20°C
solubility  insoluble in EtOH; insoluble in H2O; ≥14.8 mg/mL in DMSO
form  solid
color  Light brown to brown

Safety information for N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine

Signal word Warning
Pictogram(s)
ghs
Exclamation Mark
Irritant
GHS07
GHS Hazard Statements H302:Acute toxicity,oral
H315:Skin corrosion/irritation
H319:Serious eye damage/eye irritation
H335:Specific target organ toxicity, single exposure;Respiratory tract irritation
Precautionary Statement Codes P261:Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

Computed Descriptors for N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.